...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and Translational Allergy >The adverse drug reactions to tumor necrosis factor alpha inhibitor
【24h】

The adverse drug reactions to tumor necrosis factor alpha inhibitor

机译：对肿瘤坏死因子α抑制剂的不良药物反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundBiologic therapies targeting tumor necrosis factor alpha(TNFa) are a mainstay in the treatment of autoimmunediseases such as ankylosing spondylitis (AS), rheumatoidarthritis (RA), or Crohn’s disease (CD). With increaseduse of the biologic therapies, various adverse effects toTNFa inhibitor have been reported.MethodWe reviewed retrospectively the clinical data of subjectwho were treated with infliximab, adalimumab, or etanerceptfrom 2006 to 2012, and assessed the adversedrug reactions using electronic medical recording systemin Pusan National University Hospital.ResultsIn total, 111 subjects were enrolled. Mean age was39.8??11.7 years, and male was 68.5%. The diagnoses ofsubjects were AS (62.2%), RA (24%), CD (17%), and pyodermagangrenosum (0.9%). The injected agents wereadalimumab (53.2%), etanercept (29%), and infliximab(20.7%). Adverse drug reactions of 30.6% were reported.The most common adverse reactions were cutaneousreactions; 10 (9.0%) eczema, 4 (3.6%) injection site reaction,and 2 (1.8%) urticaria. 3.6% of subjects had a slightincrease in liver enzyme, and pulmonary tuberculosisoccurred in 2 (1.8%) patients. Mean therapy durationprior to adverse reactions was 2.1??2.2 years. Seriousadverse reaction, anaphylaxis, growth retardation, andHenoch-Sch?nlein purpura occurred in one patienteach.ConclusionThis study shows that the adverse reactions to TNFainhibitors were frequent, but most of them were mildreactions and the most common adverse reaction wascutaneous reactions.
机译：背景技术针对肿瘤坏死因子α（TNFa）的生物疗法是治疗自身免疫疾病（例如强直性脊柱炎（AS），类风湿关节炎（RA）或克罗恩病（CD））的主要手段。方法：回顾性分析2006年至2012年接受英夫利昔单抗，阿达木单抗或依那西普治疗的受试者的临床资料，并采用电子医疗记录系统评估釜山大学的药物不良反应。医院结果共纳入111名受试者。平均年龄为39.8±11.7岁，男性为68.5％。受试者的诊断为AS（62.2％），RA（24％），CD（17％）和脓疱性脓皮病（0.9％）。注射剂为阿达木单抗（53.2％），依那西普（29％）和英夫利昔单抗（20.7％）。据报道有30.6％的药物不良反应。最常见的不良反应是皮肤反应。湿疹10（9.0％），注射部位反应4（3.6％），荨麻疹2（1.8％）。 3.6％的受试者肝酶略有增加，2例（1.8％）患者发生了肺结核。不良反应发生前的平均治疗时间为2.1〜2.2年。每一例患者发生严重的不良反应，过敏反应，生长迟缓和过敏性紫癜。结论本研究表明，对TNFα抑制剂的不良反应很常见，但大多数是轻度反应，最常见的不良反应是皮肤反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号